3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Carcinoma, Non-Small-Cell Lung
12
Lung Neoplasms
8
Neoplasm Metastasis
6
Breast Neoplasms
6
Thyroid Neoplasms
4
Prostatic Neoplasms
4
Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
3
Urinary Bladder Neoplasms
2
Pleural Effusion
2
Ovarian Neoplasms
2
Kidney Neoplasms
2
Fallopian Tube Neoplasms
2
Carcinoma, Renal Cell
2
Carcinoma, Medullary
2
Urethral Neoplasms
1
Ureteral Neoplasms
1
Thyroid cancer, medullary
1
Thyroid Diseases
1
Thyroid Cancer, Papillary
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Relapsed Pediatric Solid Tumor
1
Recurrence
1
Rectal Neoplasms
1
Precancerous Conditions
1
Peritoneal Neoplasms
1
Pancreatic Neoplasms
1
Oligodendroglioma
1
Non-small Cell Lung Cancer Metastatic
1
Interventions
Gemcitabine
58
Cisplatin
32
Oxaliplatin
28
Fluorouracil
21
lenvatinib
19
durvalumab
18
Capecitabine
17
Leucovorin
15
tislelizumab
10
pembrolizumab
10
apatinib
9
Floxuridine
8
Specimen Handling
7
Panitumumab
7
Magnetic Resonance Spectroscopy
7
Albumin-Bound Paclitaxel
7
sintilimab
6
pemigatinib
6
Radiotherapy
6
Irinotecan
6
Drug Therapy
6
Biopsy
6
tremelimumab
5
regorafenib
5
olaparib
5
camrelizumab
5
Taxes
5
S 1 (combination)
5
Nivolumab
5
Folfox protocol
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2
×
Cholangiocarcinoma
×
vandetanib
×
Clear all
NCT00753675
2016-10-10
VANGOGH
Sanofi
Phase 2
Completed
174 enrolled
12 charts